This Phase 1 trial is enrolling 120 participants with acute (4 to 28 days after injury) incomplete cervical (C1 to C8) spinal cord injury to test the effect of NG004, an antibody that blocks the growth inhibitor Nogo-A, on safety and tolerability. If included, participants will be randomly assigned to receive either NG004 or placebo through repeated intrathecal injections (into the fluid surrounding the spinal cord) within 30 days. Final testing of safety, motor function and daily life functioning will be performed after 6 months.
Type
Details
DRUG: NG004 (anti-Nogo-A antibody)
Main benefits
Arm/hand function
Additional benefits
General health
Sensory function
Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.
Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn moreWings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn more